The effect of sirolimus blocks the expression of vascular endothelial growth factor as an mTOR inhibitor, which shows anti-angiogenic results in patients with GSD because of stopping the proliferation of lymphatic vessels [22]. The gene discussed is VEGFA; the disease is disorder of glycogen metabolism.